An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Chimerix (CMRX) granted 150,000 non-qualified stock options to a new employee, with an exercise price of $1.00 per share. The stock option has a 10-year term, vesting over four years. Chimerix is a biopharmaceutical company focused on developing medicines, with its most advanced program, ONC201, in development for H3 K27M-mutant glioma.
Positive
None.
Negative
None.
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c)(4).
The stock option has an exercise price per share equal to $1.00 per share, Chimerix’s closing trading price on November 20, 2023. The stock option has a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date and the remaining three-fourths vesting over the following three years in equal monthly installments. The stock option is subject to the terms of Chimerix’s 2013 Equity Incentive Plan but was granted outside of the 2013 Equity Incentive Plan.
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.
Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com
FAQ
What did Chimerix (CMRX) announce recently?
Chimerix announced the granting of 150,000 non-qualified stock options to a new employee.
How many shares can the new employee purchase with the stock options?
The new employee can purchase 150,000 shares of Chimerix's common stock.
What is the exercise price per share for the stock options?
The exercise price per share for the stock options is $1.00.
What is the vesting period for the stock options?
The stock options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date and the remaining three-fourths vesting over the following three years in equal monthly installments.
What is Chimerix's (CMRX) most advanced clinical-stage development program?
Chimerix's most advanced clinical-stage development program is ONC201, which is in development for H3 K27M-mutant glioma.
What is Chimerix's (CMRX) mission?
Chimerix's mission is to develop medicines that improve and extend the lives of patients facing deadly diseases.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
